UBS Group
AIDX

UBS Group’s 20/20 Biolabs Inc AIDX Stock Holding History

UBS Group’s Portfolio AIDX Stock Details AIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Sell
3
-8,311
-100% -$10.4K ﹤0.01% 10379
2026
Q1 		$15.6K Buy
+8,314
New +$35.1K ﹤0.01% 8109

Other funds holding AIDX

CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AUB
Atlantic Union Bankshares Glen Allen, Virginia $5.99B AUM 23.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MP
McDonald Partners Cleveland, Ohio $412M AUM 34.27% 1-Year Est. Return

UBS Group's AIDX Position: Q2 2026 in Review

UBS Group reduced its 20/20 Biolabs Inc (AIDX) stake by 100% in Q2 2026, selling an estimated $10.4K and leaving 3 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #10379.

UBS Group first reported a position in AIDX in Q1 2026 and has held it in 2 quarters since. The position peaked at $15.6K in Q1 2026. 15 funds tracked by Wall St. Rank hold AIDX as of Q2 2026.

  • UBS Group held 3 shares of 20/20 Biolabs Inc worth $2 as of Q2 2026.
  • UBS Group sold 8,311 20/20 Biolabs Inc shares in Q2 2026, an estimated $10.4K.
  • 20/20 Biolabs Inc made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10379 holding.
  • UBS Group first reported a position in 20/20 Biolabs Inc in Q1 2026 and has held it in 2 quarters since.
  • UBS Group's 20/20 Biolabs Inc position peaked at $15.6K in Q1 2026.
  • 15 funds tracked by Wall St. Rank held 20/20 Biolabs Inc as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.